The purpose of the study was to utilize axial penile buckling testing as a primary ef®cacy variable of erection quality during multi-institutional in-of®ce dose titration testing with alprostadil alfadex, prostaglandin E 1 (PGE 1 )-a-cyclodextrin, (EDEX 1 aVIRIDAL 1 , Schwarz Pharma) in patients with erectile dysfunction.
Introduction
Alprostadil alfadex, PGE 1 -a-cyclodextrin, (EDEX 1 a VIRIDAL 1 , Schwarz Pharma; U.S. Patent No. 4,054,736) is a unique formulation of prostaglandin E 1 (PGE 1 ) in which the drug substance is an inclusion complex of PGE 1 with alpha-cyclodextrin (alfadex), a cyclic glucose oligomer. In this fashion, the otherwise unstable PGE 1 moiety has enhanced chemical stability. Thus alprostadil alfadex is able to be successfully stored at a wide range of dosages from 5 to 40 mgaml and at room temperature. Alprostadil alfadex has been approved by the Food and Drug Administration as well as by numerous regulatory authorities around the world for the safe and effective treatment of male erectile dysfunction.
Prior to home use of alprostadil alfadex, of®ce-based dose titration is recommended. 1 During of®ce-based dose titration, underestimating erection quality may result in the patient increasing the dose at home with the risk of prolonged erections. Overestimating the erectile response may result in unnecessary failures and unwanted anxiety during home use. During multi-institutional clinical trials designed especially for government regulatory studies, reliable and objective documentation of the quality of erectile response during of®ce-based dose titration is critical. Previous attempts to record and verify the consistency and dependability of erection quality have involved such tests as: (i) real-time monitoring of radial (circumferential) rigidity by Rigiscan (2 ± 4), and (ii) visual analogue scales with gradings of erection. Real-time monitoring of radial (circumferential) rigidity has the disadvantage of excessive costs and the poor predictive value of the circumferential deformation data as compared with axial penile rigidity in the individual patient. 2 ± 7 Visual analogue scales are subjective, may incorporate the personal bias of the investigator and have not yet been correlated with an objective direct test of axial penile rigidity.
Axial penile rigidity is the erection quality which best characterizes its ability to be utilized successfully for vaginal penetration. Vaginal intromission and continued pelvic thrusting during intercourse apply axial compressive loads to the penile erection. An erection of inadequate axial penile rigidity will result in penile buckling, de®ned as the curving of an otherwise straight column leading to deformation when subjected to a suf®ciently large axial compressive load. 5 ± 7 Buckling of a column occurs as a result of bending the core of the column about its neutral axis. The core of the penis is solid, consisting of pressurized lacunar spaces and connecting erectile tissue of the corpora cavernosa. The measurement of penile buckling force to assess erection quality was popularized in the 1970s sleep laboratory nocturnal penile tumescence evaluations. 5 Axial penile rigidity as assessed by a userfriendly modi®ed weight scale 5 ± 7 was utilized, for the ®rst time, in multi-institutional clinical drug trials for erectile dysfunction, in which alprostadil alfadex was injected intracavernosally during of®ce-based dose titration. The overall goal was to assess the ease of use, utility and predictive value of axial penile rigidity as a clinical determinant of functional penile erection quality during the clinical trials of alprostadil alfadex. The primary aim of this report, therefore, was to correlate the outcome of the determinant axial penile rigidity with both the patient's and the investigator's opinion as to whether the erectile response realized during dose titration was adequate for satisfactory sexual intercourse. The secondary aim of this report was to further document the safety and ef®cacy of alprostadil alfadex as an intracavernosal agent for the treatment of erectile dysfunction.
Materials and methods

Study design
Three open-label studies were designed to determine the safety and ef®cacy of intracavernosal injection of alprostadil alfadex in producing erections suf®cient for sexual intercourse during inof®ce dose titration. Studies were performed as multi-center studies in 41 sites with 7, 12 and 24 centers, respectively. The study protocols were approved by the Institutional Review Board for each participating center. After written informed consent was obtained, men with erectile dysfunction for at least 6 months due to vasculogenic, neurogenic or mixed vasculogenic and neurogenic causes were enrolled. The age range in study 1 was 18 ± 65 y; in studies 2 and 3, the ages were 18 ± 75 y. All patients underwent an initial screening examination consisting of medical history, physical examination and routine laboratory evaluation including measurement of relevant hormone levels and an electrocardiogram. Patients were excluded with: (i) a diagnosis of primary hormonal or psychogenic erectile dysfunction, (ii) a history of Peyronie's disease or anatomical deformation of the penis; or (iii) a history of major medical disorders. Patients with diabetes mellitus were excluded from study 1 but included in studies 2 and 3.
The study medication consisted of ampules containing 20 mg of lyophilized alprostadil alfadex (EDEX 1 aVIRIDAL 1 , Schwarz Pharma) which were dissolved with 1 ml of sterile physiologic saline. For patients who received more than 20 mg, two ampules were dissolved in 1 ml physiologic saline. All patients received an initial open-label placebo injection. Thereafter, patients received 5 mg (study 1) or 10 mg (studies 2 and 3) alprostadil alfadex as the ®rst drug injection. Individual doses were titrated up-or downwards within 2 ± 4 additional of®ce visits within an allowed dose range of 1 ± 20 mg (study 1) and of 1 ± 40 mg (studies 2 and 3) of alprostadil alfadex.
Study endpoints
The primary ef®cacy endpoint for the clinical evaluation of erectile rigidity by the investigator was a positive penile buckling test. If the erect penis was able to support an axial loading force of 1 kg without any bending of the penile shaft ( Figure 1 ) the result was considered positive. If the shaft, however, bent with an axial loading force of 1 kg, the result was considered negative. The device used to apply the axial load consisted of a standard weight scale attached to a 2 inch diameter rigid plastic cap with a shallow concavity on its ventral surface (H. Eric Richards, Inc., Canton MA). With the patient in a supine position, the plastic cap was applied to the tip of the penis in a downward direction by the investigator. A force of 1.0 kg was slowly achieved on the weight scale by steadily increasing the downward force. The shaft of the penis was observed for buckling resulting from the load.
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Penile buckling tests were conducted within 30 min after injection, initially at the discretion of the investigator, or at the time of two consecutive circumference measurements which exceeded thē accid circumference value. Thereafter, the buckling test was performed at 10-min intervals for up to 60 min and at 15-min intervals beyond that, if required. Secondary endpoints were the evaluation of the investigator's and the patient's assessment of suf®ciency of erection for intercourse, and the selection of the lowest dose resulting in a positive penile buckling test.
Local penile side effects were documented following each injection, especially the occurrence of penile pain during injection, during and after erection, by actively questioning the patients orally (of®ce period) or in the patient diary and at each follow-up visit (home period).
Statistical analysis
Descriptive and exploratory statistics were used for the evaluation of the primary and the secondary endpoints. The number and percentage of patients with one and three consecutive positive buckling tests are presented. The patient's and physician's assessment of whether the erection was suf®cient for sexual intercourse are reported based on all injections performed. Cross tabulations were applied for the correlation of buckling test results and investigator and patient assessments. Adverse events are reported as the number and percentage of patients with local side effects or clinical adverse experiences based on the patients who received injections (intent-to-treat population).
Results
Study population
Of the 969 patients with erectile dysfunction who presented for screening in the three studies, 3 (3%), 24 (9%) and 48 (8%), respectively, discontinued before receiving alprostadil alfadex injections. The majority of these patients did not meet the inclusion or exclusion criteria or withdrew consent prior to the initial injection. The remaining 894 patients who met the inclusion and exclusion criteria formed the study population and received intracavernosal injections of alprostadil alfadex during of®ce dose titration. The characteristics of the 894 patients of the study population are described in Table 1 . The mean age of the patients in the three studies ranged between 54 and 60 y. The frequency of cardiovascular risk factors including hypertension, hypercholesterolemia and arteriosclerotic cardiovascular disease ranged between 26 and 45% of the patients. A total of 25 and 29% of the patients in studies 2 and 3 had diabetes mellitus. Effect of alprostadil alfadex on axial penile rigidity I Goldstein et al Ef®cacy data with alprostadil alfadex using axial penile rigidity
No physician reported any dif®culty with the use of the penile buckling device in any patient. No patient reported any adverse event during the repeated penile buckling tests performed during dose titration. Table 2 depicts the response to intracavernous injection of alprostadil alfadex based on the results of the penile buckling test. Overall, 71% of the patients responded with at least one positive penile buckling test within 60 min after intracavernous injection. In the three studies 86 (75%), 170 (73%), and 374 (68%) patients, respectively, responded with at least one positive penile buckling test after alprostadil alfadex injection. At least three consecutive positive buckling tests over a 20 min period were achieved in 71 (62%), 148 (64%) and 302 (55%) of the patients in the three studies, respectively.
Axial penile rigidity, as determined by the buckling test response, was compared to the investigator's evaluation of the erection's adequacy for intercourse. The presence of three consecutive positive buckling tests (ie a functionally rigid erection for 20 min) correlated with a positive patient's evaluation of the erection's adequacy for intercourse in 83% of the injections. The absence of three consecutive positive buckling tests (ie an inability to sustain a functionally rigid erection for 20 min) correlated with a negative patient's evaluation of the erection's adequacy for intercourse in 95% of the cases with the investigator's evaluation. The investigator's assessment of adequacy of erection and three positive penile buckling tests correlated in 88% of the cases whereas the inadequacy of erection and a negative buckling test correlated with the investigator's assessment in 96% of the cases.
The cumulative percentage of patients with minimum effective doses varied greatly within the dose range of 0 ± 40 mg. No patient responded to the initial in-of®ce placebo injection with an erection adequate for sexual intercourse. At 10 mg, 42% of patients in study 1 and 21% and 24% of patients in studies 2 and 3, respectively, responded with a positive penile buckling test. At 20 mg, 75% of the patients in study 1 and 40% in studies 2 and 3 responded with a positive penile buckling test. The doses of 30 mg and 40 mg were associated with positive penile buckling test responses in approximately 50% and 70% of the patients in studies 2 and 3, respectively.
Safety data with alprostadil alfadex
Detailed results are displayed in Table 3 . Penile pain occurred in 30% of the patients in all three studies combined (267a894 patients). Prolonged erections b4 h occurred in less than 1% of the study patients (2a894). Penile curvature and Peyronie's disease were documented in 3% and less than 1% of the Alprostadil alfadex is approved for the safe and effective treatment of male erectile dysfunction. Multi-institutional, prospective, placebo-controlled, double-blind clinical trials were designed and have been performed to assess the safety and ef®cacy of intracavernosal alprostadil alfadex. To maximize bene®t and minimize risk, all prospective studies using alprostadil alfadex were initiated by in-of®ce dose titration. Studies with other vasoactive agents have utilized a variety of methods to quantify the of®ce-based erectile response. 1, 9, 10 One previously employed objective determination of erectile rigidity and maintenance involves the use of on-line Rigiscan. The device was originally designed to document the quality of nocturnal penile tumescence episodes during REM sleep. This portable, battery-operated, computerbased product offered clinicians a marked advantage over previous mercury-based strain gauges which failed to record any estimation of rigidity. The Rigiscan loops are placed at the base and tip of the penile shaft. A known circumferential load is applied to the penile shaft and the amount of circumference deformation is recorded as an estimation of axial penile rigidity. 11 The major limitations for the use of this device in large multi-institutional studies include excessive costs, and more importantly, the controversy which exists in the correlation between Rigiscan-recorded radial (circum-ferential) rigidity and axial penile rigidity (penile buckling test) in the individual patient. 2 ± 7 Another economic and frequently utilized method of erection quality gradings involves the use of visual analogue scales or corresponding gradings. 1, 9 A common form of grading is a ®ve-point system in which the spectrum of erection quality ranges from absent response, tumescence without rigidity, partial rigidity, full rigidity and full rigidity with prolonged erection. As this system is subjective, it is strongly dependent on investigator andaor patient bias. Moreover, there have not been previously available prospective multi-institutional data comparing objective to subjective grade measurements of erection quality. One of the goals of this study was to perform this correlation.
It was decided to document erection quality during in-of®ce testing of alprostadil alfadex by the most direct means to clinically document functional penile rigidity for sexual intercourse. The penile buckling test involves: (i) the application of axial compressive forces to the glans of the penis; and (ii) the observation of the penile shaft for the onset of deformation or buckling. This test was introduced during the early 1970s during sleep laboratory research and remains a simple, reliable, inexpensive and underutilized diagnostic tool. 2 ± 7 Karacan et al demonstrated that a rod inserted with a force of 1.5 kg achieved vaginal intromission in all female volunteers, while forces less than 0.5 kg were unable to achieve intromission in any female subject. 13 Based on Karacan's study, it has been assumed that 500 g axial force is the minimum pressure necessary for vaginal penetration. In this investigation, a penile buckling force of 1.0 kg, representing a force mid-range between 0.5 and 1.5 kg was selected. According to Karacan et al, vaginal penetration should be able to be achieved in most female partners. The primary goal of this report, therefore, was to assess, for the ®rst time in large multiinstitutional clinical drug trials, the role of axial penile buckling as the primary ef®cacy parameter for the in-of®ce dose titration of alprostadil alfadexinduced erection quality.
The validity and reliability of axial rigidity determination was supported by the high correlations of the patient's and the physician's evaluation of erectile quality. In more than four of ®ve cases, the presence of three consecutive positive buckling tests (ie a functionally rigid erection for 20 min) correlated with a positive patient's and positive physician's evaluation of the erection's adequacy for More than 70% of the patients who were tested achieved at least one positive buckling test within 60 min after injection of alprostadil alfadex. As the patient population seems to be representative of the group of patients with erectile dysfunction in general, the estimation that about 70% of patients with erectile dysfunction are in-of®ce responders to doses between 1 and 40 mg alprostadil alfadex appears to be valid. This ®nding is also con®rmed by other studies in large patient populations where response rates of approximately 70% are reported. 10, 13 Given the fact that the of®ce-based testing was performed without any visual, auditory or vibratory sexual stimulation, the ef®cacy data in this of®ce-based dose-titration study demonstrated the effectiveness of alprostadil alfadex to induce full rigid and sustained erections.
Not surprisingly, the adverse event found most often during dose-titration was penile pain, seen in 30% of the patients. Previous reports of large studies have indicated the occurrence of penile pain in the same range. 10 However, it occurs less often in relation to the number of injections. In addition, this study may have overestimated the occurrence of penile pain due to the fact that patients were actively asked for three different qualities of penile pain (during injection, during erection and after erection) following each intracavernosal drug application.
Prolonged erections longer than 4 h occurred in frequencies similar to those previously reported. 10 ± 15 No intervention by injection of alpha-adrenergic agents or evacuation of blood from the corpora was necessary in this investigation. As recommended by other authors 10,15 ± 17 the minimum effective dose of alprostadil should be used for diagnostic evaluation and for subsequent self-injection therapy at home in order to avoid prolonged penile erections.
Penile curvatures and Peyronie's disease were documented during this of®ce study with a surprisingly high incidence rate of 3% for penile curvature and`1% for Peyronie's disease. The documentation of penile curvature and Peyronie's disease is easier when the penis is erect. 18 In fact, penile curvature and Peyronie's disease may already have been present for years in these patients, undiagnosed due to the fact that they did not achieve full rigid erections. Intracavernosal injection of alprostadil may help in these cases to uncover these diseases and initiate appropriate treatment.
Conclusions
In summary, alprostadil alfadex, PGE 1 -a-cyclodextrin, has been approved for the safe and effective treatment of patients with erectile dysfunction. Among the various choices to record and quantify physical penile rigidity during of®ce-based dose titration, axial penile rigidity measurements were utilized. This report documents, for the ®rst time, the ease of use, utility and predictive value of axial penile buckling testing as the primary ef®cacy variable of erection quality during multi-institutional in-of®ce dose titration testing. The penile buckling device has been utilized as a research tool. 4 ± 7 As the ®eld of female sexual dysfunction emerges, the determination of vaginal penetration pressure may become commonplace. The penile buckling device may see more wide clinical utilization as an assessment of erectile function in couples with sexual dysfunction.
In 894 patients with impotence b6 months, studied in 41 test sites in three different prospective studies, a series of buckling tests was performed. A positive test was associated with absent penile shaft buckling to a 1.0 kg load. A total of 71% of patients experienced at least one positive buckling test while 58% had three consecutive positive buckling tests for at least 20 minutes. In 83% and 88% of cases, respectively, three consecutive positive buckling tests following alprostadil alfadex injection correlated with the patient's and the investigator's evaluation of adequacy of erection for intercourse. Conversely in 95% and 96% of cases, respectively, the absence of three consecutive positive buckling tests following alprostadil alfadex injection correlated with the patient's and the investigator's evaluation of the inadequacy of erection for intercourse. The penile buckling test by axial loading force offers a simple, reliable and inexpensive method to quantify objectively erectile response following intracavernosal drug injection during inof®ce dose titration.
